Pulmonary arterial hypertension

Byaibio

Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pulmonary vascular resistance that increases right ventricular afterload and can progress to hypertrophy and heart failure. In the clinical setting, it has been studied in the rehab ph trial using multidimensional molecular profiling, specifically metabolomics and proteomics, to capture molecular responses and assess biomarker stability. In experimental models, PAH has been induced in rats with a single dose of monocrotaline, providing a platform to test disease mechanisms and therapies. Recent work also highlights treatment effects in this model, where melatonin showed protective effects and sildenafil improved right ventricular function. Overall, the literature emphasizes PAH as a translational disease area spanning biomarker discovery, systems-level profiling, and preclinical intervention studies. The Key Facts indicate this is a clinical-trial context for multidimensional molecular profiling, underscoring its relevance for integrated omics-based assessment.

Clinical profiling and trial analysis

  • A post-hoc analysis of the rehab ph trial used metabolomics and proteomics to study molecular responses in PAH and evaluate biomarker stability. (PMID:41849831)
  • The EBioMedicine study (PMID:41849831) specifically framed PAH as a clinical trial context for multidimensional molecular profiling.
  • metabolomics was used as a diagnostic/analytical modality in PAH to capture disease-associated molecular changes. (PMID:41849831)
  • proteomics complemented metabolomics in the same trial analysis to improve molecular characterization of PAH. (PMID:41849831)

Preclinical disease modeling and therapy

  • PAH was modeled in rats using a single dose of monocrotaline, establishing a preclinical system for disease study. (PMID:41679692)
  • The rat model reproduced key pathophysiology, including increased pulmonary vascular resistance, right ventricular afterload, hypertrophy, and heart failure. (PMID:41679692)
  • In the Molecular and Cellular Endocrinology study (PMID:41679692), melatonin was administered and showed protective effects in monocrotaline-induced PAH.
  • sildenafil improved right ventricular function in the same rat PAH model, supporting its functional benefit in disease management. (PMID:41679692)